Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Physiol ; 590(8): 1825-37, 2012 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-22331413

RESUMEN

Virtually nothing is known about the effects on fetal physiology of xanthine oxidase inhibition. This is despite maternal treatment with the xanthine oxidase inhibitor allopurinol being considered in human complicated pregnancy to protect the infant's brain from excessive generation of ROS.We investigated the in vivo effects of maternal treatment with allopurinol on fetal cardiovascular function in ovine pregnancy in late gestation. Under anaesthesia, pregnant ewes and their singleton fetus were instrumented with vascular catheters and flow probes around an umbilical and a fetal femoral artery at 118±1 dGA (days of gestational age; termca. 145 days). Five days later, mothers were infused I.V. with either vehicle (n =11) or allopurinol (n =10). Fetal cardiovascular function was stimulated with increasing bolus doses of phenylephrine (PE) following maternal vehicle or allopurinol. The effects of maternal allopurinol on maternal and fetal cardiovascular function were also investigated following fetal NO blockade (n =6) or fetal ß1-adrenergic antagonism (n =7). Maternal allopurinol led to significant increases in fetal heart rate, umbilical blood flow and umbilical vascular conductance, effects abolished by fetal ß1-adrenergic antagonism but not by fetal NO blockade. Maternal allopurinol impaired fetal α1-adrenergic pressor and femoral vasopressor responses and enhanced the gain of the fetal cardiac baroreflex. These effects of maternal allopurinol were restored to control levels during fetal NO blockade. Maternal treatment with allopurinol induced maternal hypotension, tachycardia and acid­base disturbance. We conclude that maternal treatment with allopurinol alters in vivo maternal, umbilical and fetal vascular function via mechanisms involving NO and ß1-adrenergic stimulation. The evidence suggests that the use of allopurinol in clinical practice should be approached with caution.


Asunto(s)
Sistema Cardiovascular/embriología , Sistema Cardiovascular/enzimología , Xantina Oxidasa/metabolismo , Antagonistas de Receptores Adrenérgicos beta 1/farmacología , Alopurinol/farmacología , Animales , Fenómenos Fisiológicos Cardiovasculares/efectos de los fármacos , Sistema Cardiovascular/efectos de los fármacos , Femenino , Feto/efectos de los fármacos , Feto/enzimología , Edad Gestacional , Frecuencia Cardíaca Fetal/efectos de los fármacos , Óxido Nítrico/antagonistas & inhibidores , Embarazo , Complicaciones del Embarazo/tratamiento farmacológico , Complicaciones del Embarazo/metabolismo , Flujo Sanguíneo Regional/efectos de los fármacos , Ovinos , Ácido Úrico/sangre , Xantina Oxidasa/antagonistas & inhibidores
2.
FASEB J ; 25(1): 420-7, 2011 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-20923964

RESUMEN

Molecular mechanisms predisposing people to insulin resistance are starting to emerge. Altered insulin signaling for hepatic gluconeogenesis and muscle glucose uptake is thought to play a central role. Development under suboptimal conditions is also known to increase the risk of insulin resistance in adulthood. However, the partial contributions of reduced oxygen vs. nutrient delivery to the fetus, two common adverse conditions in utero, to developmental programming of insulin resistance remain unknown. The aim of this study was to determine the effects of developmental hypoxia or undernutrition on the expression of insulin-signaling proteins in liver and skeletal muscle in adult rat offspring. We show that the expression of hepatic phospho-Akt and muscle Akt2 were significantly reduced in offspring of hypoxic, relative to offspring from normoxic or undernourished, pregnancies. Hepatic Akt-1, Akt-2, and PKCζ protein expression was reduced in offspring from both hypoxic and undernourished pregnancies. Muscle GLUT4 expression was decreased in undernourished, and further decreased in hypoxic, offspring. These findings link prenatal hypoxia to down-regulation of components of hepatic and muscle Akt expression in adult offspring. Akt may represent a pharmaceutical target for clinical intervention against the developmental programming of metabolic disease resulting from prenatal hypoxia.


Asunto(s)
Biomarcadores/metabolismo , Hipoxia/fisiopatología , Resistencia a la Insulina/fisiología , Efectos Tardíos de la Exposición Prenatal , Animales , Western Blotting , Peso Corporal , Femenino , Transportador de Glucosa de Tipo 4/metabolismo , Insulina/sangre , Lípidos/sangre , Tamaño de la Camada , Hígado/metabolismo , Masculino , Desnutrición/fisiopatología , Músculo Esquelético/metabolismo , Embarazo , Proteína Quinasa C/metabolismo , Proteínas Proto-Oncogénicas c-akt/metabolismo , Ratas , Ratas Wistar , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA